Novel thrombolytic drugs: Will they make a difference in the treatment of ischaemic stroke?

CNS Drugs

Volumn 22, Issue 8, 2008, Pages 619-629

  Meretoja, Atte ^a   Tatlisumak, Turgut ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Alteplase, therapeutic use; Desmoteplase, pharmacodynamics; Desmoteplase, pharmacokinetics; Desmoteplase, therapeutic use; Research and development; Stroke, treatment; Tenecteplase, pharmacodynamics; Tenecteplase, therapeutic use

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DESMOTEPLASE; FIBRINOLYTIC AGENT; PLACEBO; PROUROKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOPPLER ECHOGRAPHY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MOLECULAR WEIGHT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECANALIZATION; REVIEW; STROKE; ULTRASOUND THERAPY;

ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 46749136004     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822080-00001     Document Type: Review

References (73)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006 May 27; 367 (9524): 1747-57
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics: 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 Feb 6; 115 (5): e69-171
3. Tiainen M, Poutiainen E, Kovala T, et al. Cognitive and neurophysiological outcome of cardiac arrest survivors treated with therapeutic hypothermia. Stroke 2007 Aug; 38 (8): 2303-8
4. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007 May; 87 (1): 179-97
5. Saver JL. Time is brain: quantified. Stroke 2006 Jan; 37 (1): 263-6
6. Wardlaw JM, Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; (3): CD000213
7. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004 Jul; 61 (7): 1066-70
8. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004 Mar 6; 363 (9411): 768-74
9. Stroke trials registry: ECASS III [online]. Available from URL: http://strokecenter.org/trials/ [Accessed 2007 Jul 28]
10. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999 Aug 28; 354 (9180): 716-22
11. Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic Therapy in Acute Ischemic Stroke Study Investigators. Stroke 2000 Apr; 31 (4): 811-6
12. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999 Dec 1; 282 (21): 2019-26
13. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004 Nov 18; 351 (21): 2170-8
14. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006 May; 37 (5): 1227-31
15. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005 Jan; 36 (1): 66-73
16. Hacke W. Desmoteplase in Acute Ischemic Stroke-2 (DIAS-2) trial [oral presentation]. XVI European Stroke Conference; 2007 May 29-Jun 1; Glasgow
17. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995 Oct 4; 274 (13): 1017-25
18. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998 Oct 17; 352 (9136): 1245-51
19. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999 Dec; 30 (12): 2598-605
20. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke study. Stroke 2004 Apr; 35 (4): 904-11
21. The Interventional Management of Stroke (IMS) II study. Stroke 2007 Jul; 38 (7): 2127-35
22. Stroke trials registry: IMS -III [online]. Available from URL: http://strokecenter.org/trials/ [Accessed 2007 Jul 28]
23. Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke 2007 Oct; 38 (10): 2633-9
24. Stroke trials registry: MR RESCUE [online]. Available from URL: http://strokecenter.org/trials/ [Accessed 2007 Nov 28]
25. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995 Dec 14; 333 (24): 1581-7
26. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators: Prolyse in Acute Cerebral Thromboembolism. Stroke 1998 Jan; 29 (1): 4-11
27. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999 Dec 1; 282 (21): 2003-11
28. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007 Jan 27; 369 (9558): 275-82
29. ClinicalTrials.gov. Study of tenecteplase (TNK) in acute ischemic stroke (TNK-S2B). Identifier NCT00252239 [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00252239 [Accessed 2007 Jul 28]
30. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. Stroke 1994 Nov; 25 (11): 2220-6
31. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scott Med J 1957 May; 2 (5): 200-15
32. van Swieten JC, Koudstall PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1998 May; 19 (5): 604-7
33. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 2007 Aug; 38 (8): 2279-83
34. Schumacher HC, Bateman BT, Boden-Albala B, et al. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide; Inpatient Sample 1999 to 2004. Ann Emerg Med 2007 Aug; 50 (2): 99-107
35. Lindsberg PJ, Happola O, Kallela M, et al. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology 2006 Jul 25; 67 (2): 334-6
36. Boode B, Welzen V, Franke C, et al. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis 2007; 23 (4): 294-8
37. Kaste M. Evidence, education and practice. Cerebrovasc Dis 2006; 22 (5-6): 342-9
38. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007 Mar; 38 (3): 967-73
39. Christou I, Alexandrov AV, Burgin WS, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke 2000 Aug; 31 (8): 1812-6
40. Sugg RM, Noser EA, Shaltoni HM, et al. Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. AJNR Am J Neuroradiol 2006 Apr; 27 (4): 769-73
41. Tsivgoulis G, Alexandrov AV. Ultrasound-enhanced thrombolysis in acute ischemic stroke: potential, failures, and safety. Neurotherapeutics 2007 Jul; 4 (3): 420-7
42. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005 Jul; 36 (7): 1432-8
43. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke: results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006 Jun-Jul; 27 (6): 1177-82
44. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005 Oct; 36 (10): 2311-20
45. Nikas D, Reimers B, Elisabetta M, et al. Percutaneous interventions in patients with acute ischemic stroke related to obstructive atherosclerotic disease or dissection of the extracranial carotid artery. J Endovasc Ther 2007 Jun; 14 (3): 279-88
46. Meretoja A, Tatlisumak T. Thrombolytic therapy in acute ischemic stroke: basic concepts. Curr Vasc Pharmacol 2006 Jan; 4 (1): 31-44
47. Hawkey C. Plasminogen activator in saliva of the vampire bat Desmodus rotundus. Nature 1966 Jul 23; 211 (5047): 434-5
48. Gardell SJ, Duong LT, Diehl RE, et al. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989 Oct 25; 264 (30): 17947-52
49. Kratzschmar J, Haendler B, Langer G, et al. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1991 Sep 15; 105 (2): 229-37
50. Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995 Oct 27; 270 (43): 25596-603
51. Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci U S A 1984 Sep; 81 (17): 5355-9
52. Renatus M, Stubbs MT, Huber R, et al. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. Biochemistry 1997 Nov 4; 36 (44): 13483-93
53. Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005 Jun; 36 (6): 1241-6
54. Lopez-Atalaya JP, Roussel BD, Ali C, et al. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007 Mar; 38 (3): 1036-43
55. Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003 Feb; 34 (2): 537-43
56. Muschick P, Zeggert D, Donner P, et al. Thrombolytic properties of Desmodus (Vampire Bat) salivary plasminogen activator DSPAα1, alteplase and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis. Fibrinolysis 1993; 7 (4): 284-90
57. Hare TR, Gardell SJ. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation. Thromb Haemost 1992 Aug 3; 68 (2): 165-9
58. Witt W, Baldus B, Bringmann P, et al. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992 Mar 1; 79 (5): 1213-7
59. Meden P, Tatlisumak T, Takano K, et al. Thrombolysis with recombinant Desmodus saliva plasminogen activator (rD-SPAμ1) in a rat embolic stroke model [abstract]. Cerebrovasc Dis 1996; 6 (3): 190
60. Witt W, Maass B, Baldus B, et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs: fast and persistent recanalization by intravenous bolus administration. Circulation 1994 Jul; 90 (1): 421-6
61. Tanswell P, Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992 Apr; 19 (5): 1071-5
62. Bell WR. Present-day thrombolytic therapy: therapeutic agents: pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 2002; 3 Suppl. 2: S34-44
63. Modi NB, Fox NL, Clow FW, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000 May; 40 (5): 508-15
64. Mahoney FI, Barthel D. Functional evaluation: the Barthel Index. Md State Med J 1965 Feb; 14: 56-61
65. Haley Jr EC, Lyden PD, Johnston KC, et al. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005 Mar; 36 (3): 607-12
66. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994 Apr 26; 91 (9): 3670-4
67. Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic theraphy of acute myocardial infarction. Clin Pharmacokinet 2002; 41 (15): 1229-45
68. Van de Werf F, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001 Dec; 22 (24): 2253-61
69. Thomas GR, Thibodeaux H, Errett CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994 Oct; 25 (10): 2072-8
70. Chapman DF, Lyden P, Lapchak PA, et al. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001 Mar; 32 (3): 748-52
71. Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 2004 Jan; 185 (1): 154-9
72. Khatri P, Broderick JP, Pancioli AM. Risk of thrombolysis-associated intracerebral hemorrhage: the need to compare apples with apples [letter]. Stroke 2005 Jun; 36 (6): 1109-10
73. Stroke trials registry: TNKilas trial [online]. Available from URL: http://strokecenter.org/trials/ [Accessed 2007 Jul 28]